<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:34:40Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10630984" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10630984</identifier>
        <datestamp>2023-11-07</datestamp>
        <setSpec>nihpa</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-journal-id">0370465</journal-id>
              <journal-id journal-id-type="pubmed-jr-id">398</journal-id>
              <journal-id journal-id-type="nlm-ta">Am Heart J</journal-id>
              <journal-id journal-id-type="iso-abbrev">Am Heart J</journal-id>
              <journal-title-group>
                <journal-title>American heart journal</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0002-8703</issn>
              <issn pub-type="epub">1097-6744</issn>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10630984</article-id>
              <article-id pub-id-type="pmcid">PMC10630984</article-id>
              <article-id pub-id-type="pmc-uid">10630984</article-id>
              <article-id pub-id-type="pmid">37088164</article-id>
              <article-id pub-id-type="pmid">37088164</article-id>
              <article-id pub-id-type="doi">10.1016/j.ahj.2023.04.009</article-id>
              <article-id pub-id-type="manuscript">nihpa1940242</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction – A post hoc analysis of the cel-02 phase IIa study</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rikken</surname>
                    <given-names>Sem A.O.F.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bor</surname>
                    <given-names>Willem L.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="A1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Selvarajah</surname>
                    <given-names>Abi</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zheng</surname>
                    <given-names>Kai L.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="A1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hack</surname>
                    <given-names>Amy P.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="A1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gibson</surname>
                    <given-names>C. Michael</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="A4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Granger</surname>
                    <given-names>Christopher B.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="A5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bentur</surname>
                    <given-names>Ohad S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="A6" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Coller</surname>
                    <given-names>Barry S.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="A6" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>van ’t Hof</surname>
                    <given-names>Arnoud W.J.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A7" ref-type="aff">g</xref>
                  <xref rid="A8" ref-type="aff">h</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>ten Berg</surname>
                    <given-names>Jurriën M.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="A7" ref-type="aff">g</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>a</label>St. Antonius Hospital, Nieuwegein, The Netherlands</aff>
              <aff id="A2"><label>b</label>Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands</aff>
              <aff id="A3"><label>c</label>Department of Cardiology, Isala Heart Center, Zwolle, The Netherlands</aff>
              <aff id="A4"><label>d</label>Boston Clinical Research Institute, Boston, MA</aff>
              <aff id="A5"><label>e</label>Department of Cardiology, Duke University School of Medicine, Durham, NC</aff>
              <aff id="A6"><label>f</label>Rockefeller University, Allen and Frances Adler Laboratory of Blood and Vascular Biology, New York, NY</aff>
              <aff id="A7"><label>g</label>Department of Cardiology, MUMC+, Maastricht, The Netherlands</aff>
              <aff id="A8"><label>h</label>Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands</aff>
              <author-notes>
                <corresp id="CR1">Reprint requests: Sem A.O.F. Rikken, MD, Department of Cardiology, St. Antonius Hospital, PO Box 2400 – internal post address E1 t.a.v. Cardiologie, Koekoekslaan 1, 3430 VB, Nieuwegein, The Netherlands.</corresp>
              </author-notes>
              <pub-date pub-type="nihms-submitted">
                <day>2</day>
                <month>11</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>8</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>22</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>08</day>
                <month>11</month>
                <year>2023</year>
              </pub-date>
              <volume>262</volume>
              <fpage>75</fpage>
              <lpage>82</lpage>
              <permissions>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the CC BY-NC-ND license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>)</license-p>
                </license>
              </permissions>
              <abstract id="ABS1">
                <sec id="S1">
                  <title>Background</title>
                  <p id="P1">Zalunfiban (RUC-4) is a novel, subcutaneously administered glycoprotein IIb/IIIa inhibitor (GPI) designed for prehospital treatment to initiate reperfusion in the infarct-related artery (IRA) before primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction (STEMI). Since GPIs have been reported to rapidly reperfuse IRAs, we assessed whether there was a dose-dependent relationship between zalunfiban treatment and angiographic reperfusion indices and thrombus grade of the IRA at initial angiogram in patients with STEMI.</p>
                </sec>
                <sec id="S2">
                  <title>Methods</title>
                  <p id="P2">This was a post hoc analysis from the open-label Phase IIa study that investigated the pharmacodynamics, pharmacokinetics, and tolerability of three doses of zalunfiban – 0.075, 0.090 and 0.110 mg/kg - in STEMI patients. This analysis explored dose-dependent associations between zalunfiban and three angiographic indices of the IRA, namely coronary and myocardial blood flow and thrombus burden. Zalunfiban was administered in the cardiac catheterization laboratory prior to vascular access, ~10 to 15 minutes before the initial angiogram. All angiographic data were analyzed by a blinded, independent, core laboratory.</p>
                </sec>
                <sec id="S3">
                  <title>Results</title>
                  <p id="P3">Twentyfour out of 27 STEMI patients were evaluable for angiographic analysis (0.075 mg/kg [n=7], 0.090 mg/kg [n=9], and 0.110 mg/kg [n=8]). TIMI flow grade 2 or 3 was seen in 1/7 patients receiving zalunfiban at 0.075 mg/kg, in 6/9 patients receiving 0.090 mg/kg, and in 7/8 patients receiving 0.110 mg/kg (p<sub>trend</sub> = 0.004). A similar trend was observed based on TIMI flow grade 3. Myocardial perfusion was also related to zalunfiban dose (p<sub>trend</sub> = 0.005) as reflected by more frequent TIMI myocardial perfusion grade 3. Consistent with the dose-dependent trends in greater coronary and myocardial perfusion, TIMI thrombus ≥4 grade was inversely related to zalunfiban dose (p<sub>trend</sub> = 0.02).</p>
                </sec>
                <sec id="S4">
                  <title>Conclusion</title>
                  <p id="P4">This post hoc analysis found that higher doses of zalunfiban administered in the cardiac catheterization lab prior to vascular access were associated with greater coronary and myocardial perfusion, and lower thrombus burden at initial angiogram in patients with STEMI undergoing primary percutaneous coronary intervention.</p>
                </sec>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="S5">
              <title>Background</title>
              <p id="P5">Early restoration of blood flow to the myocardium is essential for improved survival in patients presenting with ST-elevation myocardial infarction (STEMI).<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Primary percutaneous coronary intervention (pPCI) has been shown to be superior to fibrinolytic therapy and fibrinolytic-facilitated pPCI on clinical outcome, particularly when an interventional facility is readily accessible. Nevertheless, delays in achieving reperfusion are unavoidable, as patients must be transported to the cardiac catheterization laboratory (CCL) and wait until balloon inflation.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> In fact, only 61.8% of STEMI patients received pPCI within the recommended time limits in a recent prospective European registry of 11,462 patients.<sup><xref rid="R4" ref-type="bibr">4</xref></sup></p>
              <p id="P6">Efforts to restore blood flow during transportation or before pPCI may negate the deleterious effects of delays. Platelet glycoprotein IIb/IIIa inhibitors (GPI) given intravenously before pPCI have been demonstrated to effectively improve coronary and myocardial reperfusion in patients with STEMI, in particular when given during transport to the hospital.<sup><xref rid="R5" ref-type="bibr">5</xref>-<xref rid="R7" ref-type="bibr">7</xref></sup> The On-TIME 2 trial, which randomized and treated STEMI patients within the ambulance to high bolus dose of tirofiban or placebo in addition to standard care, demonstrated significantly improved rates of myocardial perfusion, lower major adverse cardiac events, and no increase in major bleeding in the tirofiban group compared to the placebo group.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> However, first-generation intravenous GPIs have been associated with major bleeding in some trials, which limits their benefit and led to a decline in routine upstream GPI treatment.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> Much of the bleeding initially associated with GPIs was femoral artery access site hemorrhage, which was subsequently diminished by adopting radial artery access.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Importantly, early use of first-generation intravenous GPIs did not increase the rate of major bleeding compared to late administration in a meta-analysis.<sup><xref rid="R12" ref-type="bibr">12</xref></sup></p>
              <p id="P7">Zalunfiban (RUC-4) is a novel, second-generation, short-acting, subcutaneously administered small molecule inhibitor of the platelet GPIIb/IIIa receptor specifically designed to facilitate treatment during first medical contact (FMC). It was well tolerated by healthy volunteers and patients with stable coronary artery disease taking aspirin in a Phase I study.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> In the Phase IIa study, zalunfiban at doses between 0.075-0.110 mg/kg showed dose-dependent inhibition of platelet function within 15 minutes after administration and platelet function returned to normal within 4 hours.<sup><xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref></sup> Whether zalunfiban improves epicardial and myocardial perfusion, and reduces thrombus burden before pPCI is unknown. Thus, the objective of the present post hoc analysis was to explore whether there is a dose-dependent association between zalunfiban administration prior to vascular access and angiographic indices of the infarct-related artery (IRA) approximately 10-15 minutes after administration, and immediately prior to pPCI.</p>
            </sec>
            <sec id="S6">
              <title>METHODS</title>
              <sec id="S7">
                <title>Study protocol, population and procedures</title>
                <p id="P8">The Phase IIa study (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04284995" ext-link-type="uri">NCT04284995</ext-link>) was a prospective, open-label, single-center study investigating the pharmacodynamics (PD), pharmacokinetics (PK), and tolerability of three increasing, weight-adjusted, doses of zalunfiban in STEMI patients undergoing pPCI. The study protocol and the results of the study have been previously published.<sup><xref rid="R14" ref-type="bibr">14</xref></sup></p>
                <p id="P9">In brief, adult STEMI patients presenting within 6 hours of symptom onset in whom pPCI was planned, and who had not previously received oral anticoagulants or intravenous GPIs were assessed for eligibility in the CCL. Verbal informed consent was provided by all patients before treatment administration and written informed consent was obtained before hospital discharge. The angiographic population studied in this analysis included all patients with evaluable angiographic data and without a definite type 2 myocardial infarction.</p>
                <p id="P10">All patients received usual care for STEMI in the ambulance, including aspirin (500 mg IV), ticagrelor (180 mg oral), and unfractionated heparin (5,000 IU IV). Zalunfiban was administered at the CCL prior to vascular access, which was estimated to be 10-15 minutes before initial angiography. Samples to assess zalunfiban PK/PD were obtained at 15, 30, 45, 60, 90, 120, 180 minutes and 240 minutes after drug administration. If a patient was not evaluable for PK/PD analysis, but had been enrolled, extra patients were enrolled to have at least eight evaluable patients per cohort. PD were measured with the VerifyNow P2Y<sub>12</sub> cartridge using the thrombin receptor activating peptide channel.<sup><xref rid="R16" ref-type="bibr">16</xref></sup></p>
              </sec>
              <sec id="S8">
                <title>Study outcomes</title>
                <p id="P11">The primary analysis was of the dose-dependent effects of zalunfiban on three angiographic indices of the IRA at initial angiography. Coronary and myocardial flow were assessed using the Thrombolysis in Myocardial Infarction (TIMI) flow grade and TIMI myocardial perfusion grade systems, respectively.<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> TIMI flow grade 2 or 3 were combined to assess the presence of substantial coronary perfusion since both TIMI grade 2 and 3 have been shown to be associated with improved outcomes relative to TIMI grades 0 or 1, but TIMI flow grade 3 was assessed alone in the sensitivity analysis.<sup><xref rid="R18" ref-type="bibr">18</xref>-<xref rid="R20" ref-type="bibr">20</xref></sup> Angiographic thrombus burden was classified using the TIMI thrombus grade system, and high thrombus burden was dichotomized to grade ≥4 (i.e., greatest thrombus dimension &gt;2 vessel diameters).<sup><xref rid="R21" ref-type="bibr">21</xref></sup> All angiographic data were analyzed by a blinded, independent, core laboratory (Boston Clinical Research Institute, Boston MA, United States of America).</p>
                <p id="P12">Secondary analyses included the dose-dependent correlations between the three angiographic indices of interest and PK/PD values at 15 minutes post dose, which approximated the time of initial angiography. Other objectives included infarct size estimation using high sensitivity cardiac troponin T (hs-cTnT, Roche Diagnostics<sup>®</sup>, Basel, Switzerland) and creatinine kinase-muscle/brain (CK-MB) levels at 24 hours post-pPCI. Bleeding events were assessed according to the Bleeding Academic Research Consortium (BARC) criteria and classified by type of bleeding.<sup><xref rid="R22" ref-type="bibr">22</xref></sup></p>
              </sec>
              <sec id="S9">
                <title>Statistical analysis</title>
                <p id="P13">Normally distributed data are presented as mean and standard deviation and non-normally distributed data as median and interquartile range. Categorical data are summarized as frequency counts and percentages. Dose-dependent relationships between zalunfiban and angiographic indices of the IRA at initial angiogram were assessed using Cochran-Armitage tests. The Spearman coefficient was used to assess the correlation between PK/PD values 15 minutes post-administration and the angiographic indices of the IRA at initial angiogram among the subset of cases where PK/PD data were available. Infarct size was compared based on hs-cTnT and CK-MB levels between groups with Kruskal-Wallis test. Given the small number of patients/events per cohort and in line with previously published studies, multivariable adjustment was not performed. Missing PD data for correlation with the angiographic indices of the IRA at initial angiogram were not imputed. Significance level was set to <italic toggle="yes">P</italic> &lt; .05. All analyses were performed using R 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria).</p>
              </sec>
            </sec>
            <sec id="S10">
              <title>RESULTS</title>
              <sec id="S11">
                <title>Study population</title>
                <p id="P14">Between June 2020 and October 2020, 27 patients were enrolled upon arrival at the CCL (cohort 1 - 0.075 mg/kg [n=8], cohort 2 - 0.090 mg/kg [n=9], and cohort 3 - 0.110 mg/kg [n=10]). Of these, 24 patients were included in the angiographic population [<xref rid="F1" ref-type="fig">Figure 1</xref>]. The reasons for being unevaluable were: withdrawal of informed consent (1 patient in cohort 3), no recording of contrast injection before pPCI (1 patient in cohort 3), and change in diagnosis from STEMI to perimyocarditis without coronary artery disease (1 patient in cohort 1). Demographics, baseline characteristics, and time intervals are reported in <xref rid="T1" ref-type="table">Table I</xref>.</p>
              </sec>
              <sec id="S12">
                <title>Dose-response relationship to angiographic indices</title>
                <p id="P15">TIMI flow grade 2 or 3 of the IRA at initial angiography was observed in 1/7 patients receiving zalunfiban at 0.075 mg/kg, in 6/9 patients receiving 0.090 mg/kg, and in 7/8 patients receiving 0.110 mg/kg (p<sub>trend</sub> = 0.004, <xref rid="F2" ref-type="fig">Figure 2</xref>). Greater coronary flow with higher doses of zalunfiban was also observed in a sensitivity analysis that only looked at TIMI flow grade 3 (1/7 vs 5/9 vs 6/8, p<sub>trend</sub> = 0.02). Similarly, greater myocardial perfusion was observed in patients receiving higher doses, reflected by 1 out 7 patients reaching TIMI myocardial perfusion grade 3 at initial angiography in cohort 1 versus 5/9 in cohort 2 and 7/8 in cohort 3 (p<sub>trend</sub> = 0.005). Consistent with the dose-dependent trends in coronary and myocardial perfusion, high thrombus burden was present in 6/7 patients in cohort 1, 3/9 patients in cohort 2, and 2/8 patients in cohort 3 (p<sub>trend</sub> = 0.02).</p>
                <p id="P16">Both platelet inhibition (<italic toggle="yes">ρ</italic><sub>Spearman</sub> = 0.50, <italic toggle="yes">P</italic> = .018) and the zalunfiban blood concentration (<italic toggle="yes">ρ</italic><sub>Spearman</sub> = 0.43, <italic toggle="yes">P</italic> = .048) measured at 15 minutes after administration demonstrated positive correlations with TIMI flow grade (<xref rid="SD1" ref-type="supplementary-material">Figure S1</xref>). Similarly, myocardial perfusion was positively correlated with platelet inhibition (<italic toggle="yes">ρ</italic><sub>Spearman</sub> = 0.48, <italic toggle="yes">P</italic> = .024) and zalunfiban blood concentration (<italic toggle="yes">ρ</italic><sub>Spearman</sub> = 0.45, <italic toggle="yes">P</italic> = .037). Thrombus burden was negatively associated with both platelet inhibition (<italic toggle="yes">ρ</italic><sub>Spearman</sub> = −0.31, <italic toggle="yes">P</italic> = .16) and zalunfiban blood concentration (<italic toggle="yes">ρ</italic><sub>Spearman</sub> = −0.48, <italic toggle="yes">P</italic> = .022).</p>
              </sec>
              <sec id="S13">
                <title>Infarct size</title>
                <p id="P17">Median hs-cTnT and CK-MB levels at 24 hours post-pPCI were lower in patients receiving the higher doses of zalunfiban, but the differences were not statistically significant between the cohorts (hs-cTnT, μg/L: 1.25 [0.37, 3.82] vs 0.79 [0.24, 2.32] vs 0.44 [0.42, 2.59], <italic toggle="yes">P</italic> = .93; CK-MB, U/L: 48.0 [32.5, 68.0] vs 46.0 [24.0, 99.0] vs 30.0 [27.0, 59.5], <italic toggle="yes">P</italic> = .76), <xref rid="SD1" ref-type="supplementary-material">Table SI</xref>.</p>
              </sec>
              <sec id="S14">
                <title>Safety</title>
                <p id="P18"><xref rid="T2" ref-type="table">Table II</xref> displays the bleeding events for all the patients included in the angiographic analysis population. Nine patients had at least one BARC 1 bleeding event (3/7 vs 4/9. vs 2/8), and two patients had one or more BARC 2 bleeding event (1 in cohort 1 and 1 in cohort 3). One BARC 3a bleeding event occurred in cohort 3 and one BARC 3b bleeding occurred in cohort 1. There were no BARC 4 or BARC 5 bleeding events.</p>
              </sec>
            </sec>
            <sec id="S15">
              <title>DISCUSSION</title>
              <p id="P19">This post hoc analysis investigated the dose-related effects of zalunfiban on three angiographic indices of the IRA prior to pPCI. We found a statistically significant dose-dependent association between zalunfiban and these angiographic indices of interest, namely TIMI flow grade 2 and 3, TIMI myocardial perfusion grade 3, and TIMI thrombus grade ≥4. A similar dose-dependent trend was observed with TIMI flow grade 3. The improved angiographic indices also correlated with both platelet inhibition and zalunfiban blood levels measured 15 minutes after administration. Median levels of Hs-cTnT and CK-MB were lower in patients receiving higher doses of zalunfiban, suggesting smaller infarct sizes, but the differences were not statistically significant. The majority of bleeding events were BARC 1 and there was no correlation between zalunfiban dose and BARC 1, 2, or 3 bleeding events.</p>
              <p id="P20">Several strategies have been investigated to accelerate epicardial and myocardial reperfusion and to reduce thrombus burden alone or before pPCI. Fibrinolytic therapy alone improves reperfusion in some patients with STEMI, but is inferior on clinical outcome compared with pPCI alone when pPCI is performed timely.<sup><xref rid="R23" ref-type="bibr">23</xref></sup> Some reperfusion benefit with prehospital fibrinolysis before pPCI was observed in patients with early STEMI who could not undergo pPCI within 1 hour after FMC as reflected by significantly fewer patients with TIMI flow grade 0 on initial angiography.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> However, prehospital fibrinolytic therapy before pPCI did not lead to improved clinical outcome and an increase in in stroke was observed.</p>
              <p id="P21">Alternative strategies such as thrombus aspiration before pPCI have been studied to improve reperfusion.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> By performing thrombus aspiration before pPCI, there is a potential decrease in distal embolization during PCI, ultimately improving myocardial reperfusion and reducing the likelihood of no-reflow. Since no-reflow remains a significant problem for many STEMI patients, even when their epicardial arteries are patent, extensive research has been conducted on this technique.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> Thrombus aspiration before pPCI was compared with pPCI alone in the small, single-center randomized TAPAS trial and showed lower thrombus burden and improved myocardial perfusion. At 12-month follow-up, rates of reinfarction and survival improved substantially, but the study was not powered for clinical outcomes.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> Later, 2 large randomized-controlled trials powered for clinical outcome, TASTE and TOTAL, challenged the results of the TAPAS trial.<sup><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup> Both trials reported no benefit with routine thrombus aspiration before pPCI on clinical outcome, despite improved rates of myocardial reperfusion and lower distal embolization.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> Importantly, several meta-analyses corroborated the lack of benefit with routine thrombus aspiration and additionally found a significant, albeit marginal, increased risk of stroke with the use of thrombus aspiration before pPCI.<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup> This led to class III recommendation for routine thrombus aspiration and moved research towards prehospital antiplatelet strategies to improve reperfusion and reduce thrombus burden.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup></p>
              <p id="P22">Prehospital treatment with the oral P2Y<sub>12</sub> inhibitor ticagrelor was investigated in the ATLANTIC trial and showed no improvement in reperfusion prior to PCI nor in cardiovascular outcomes compared to in-hospital administration.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> Studies of platelet function in the ATLANTIC study demonstrated that it took several hours for the majority of patients to achieve the maximum antiplatelet effect, with opioid medications further delaying the onset of action.<sup><xref rid="R33" ref-type="bibr">33</xref></sup> This led to updating of the labeling of oral P2Y12 inhibitors to include the recommendation to “consider the use of a parenteral antiplatelet agent in acute coronary syndrome patients requiring coadministration of morphine or other opioid agonists.”</p>
              <p id="P23">In contrast, prehospital administration of the GPI tirofiban improved myocardial reperfusion and improved ischemic outcomes without increasing major bleeding in 984 STEMI patients in the On-TIME 2 trial.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Similar data, including increased TIMI blood flow scores at initial angiography and reduced mortality, were reported in several meta-analyses of early versus late administration of all of the GPIs.<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup> Our data provide first-in-human evidence of a dose-dependent association between upstream treatment with zalunfiban and improved indices of epicardial and myocardial perfusion in early presenting patients with STEMI. In addition, both epicardial and myocardial reperfusion indices correlated with the degree of platelet inhibition and zalunfiban plasma concentration. Likewise, in a study in which 13 patients with STEMI underwent angiography (9 showing TIMI 0 and 4 TIMI 1 blood flow in the target vessel), were given abciximab, and then restudied by angiography 10 minutes later, demonstrated an increase of at least one TIMI grade in 11 patients, with 7 reaching TIMI grade 2 or 3.<sup><xref rid="R36" ref-type="bibr">36</xref></sup></p>
              <p id="P24">A post hoc analysis from On-TIME 2 trial provided additional important insights on the timing of GPI treatment, showing that the greatest efficacy was observed when the drug was given shortly after symptom onset, which was also supported by a higher incidence of aborted myocardial infarction.<sup><xref rid="R37" ref-type="bibr">37</xref></sup> This time-dependent effect may be explained by the observation that fresh thrombi are more rich in platelets, and therefore more to still be dynamic, which makes them more likely to benefit from potent antiplatelet therapy.<sup><xref rid="R38" ref-type="bibr">38</xref></sup> Our results corroborate these findings with zalunfiban and show that higher doses of zalunfiban were associated with lower thrombus burden at initial angiogram in early presenting patients with STEMI, which correlated with the extent of platelet inhibition.</p>
              <p id="P25">Despite a body of evidence supporting its effectiveness, routine upstream GPI treatment in early presenting patients with STEMI is currently not endorsed by European and American guidelines.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R15" ref-type="bibr">15</xref></sup> This partly reflects the difficulties of administering an intravenous drug as a bolus followed by a continuous infusion under emergency conditions and the unfavorable safety profile of first-generation GPIs. Bleeding events associated with first-generation GPIs may have been caused by multiple factors, including the prolonged half-life of these drugs, the need for extended infusion after the initial bolus, and frequent use of femoral access.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> It’s worth noting that in the phase IIa study, no correlation was found between zalunfiban dose and major bleeding.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> Finally, differences in study designs and patient populations (such as time from symptom onset to GPI administration, time from GPI to initial angiogram, high-risk vs low-risk) need to be considered when drawing conclusions on the net clinical benefit of upstream GPI treatment in early presenting patients with STEMI, especially considering the specific design features of zalunfiban. <sup><xref rid="R8" ref-type="bibr">8</xref>-<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R39" ref-type="bibr">39</xref></sup></p>
              <p id="P26">Zalunfiban is a second-generation GPI and has been specifically designed to be easy to administer under emergency conditions and to have a rapid offset of action, with a reduction in platelet inhibition to under 50% within approximately two hours, to minimize the risk of bleeding while offering protection against thrombosis until the oral P2Y<sub>12</sub> inhibitors reach their maximal antiplatelet effects. Zalunfiban is now being tested in a Phase III randomized, placebo-controlled, blinded study (CeleBrate; <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04825743" ext-link-type="uri">NCT04825743</ext-link>) to assess whether it improves clinical outcomes and reperfusion prior to pPCI.<sup><xref rid="R40" ref-type="bibr">40</xref></sup></p>
              <p id="P27">This exploratory post hoc analysis has several limitations. First, this analysis was not powered for the assessment of angiographic outcomes so the results should be interpreted as hypothesis generating only. Second, exact times from zalunfiban administration to initial coronary angiography of IRA were not recorded and thus are provided as estimates. However, the estimates are based on robust retrospective data. Third, some angiographic and PK/PD were missing or unevaluable due to the post hoc nature of the current analysis. However, missing values were distributed equally among the cohorts.</p>
              <p id="P28">In conclusion, higher doses of zalunfiban given prior to vascular access were associated with greater patency of the IRA, greater myocardial perfusion, and lower thrombus burden. These correlated with both the platelet inhibition and blood levels produced by zalunfiban 15 minutes after administration. The effects of very early zalunfiban administration, i.e. at FMC by paramedics in STEMI patients presenting within &lt;4 hours of symptom onset, on clinical outcome are currently being investigated in the CeleBrate trial.</p>
            </sec>
            <sec sec-type="supplementary-material" id="SM1">
              <title>Supplementary Material</title>
              <supplementary-material id="SD1" position="float" content-type="local-data">
                <label>Coller et al - Supplementary</label>
                <media xlink:href="NIHMS1940242-supplement-Coller_et_al_-_Supplementary.docx" id="d64e574" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="S16">
              <title>Acknowledgments</title>
              <p id="P29">The authors would like to thank the team of the Boston Clinical Research Institute for analyzing the angiograms.</p>
              <sec id="S17">
                <title>Funding</title>
                <p id="P30">The Phase IIA study was funded by CeleCor Therapeutics, Inc . Also supported, in part, by grant 19278 from the National Heart, Lung and Blood Institute and a Clinical and Translational Science Award (CTSA) UL1TR001866 from the National Institutes of Health, National Center for Advancing Translational Science (NCATS) to B.S.C.</p>
              </sec>
            </ack>
            <fn-group>
              <fn fn-type="COI-statement" id="FN1">
                <p id="P31">Conflict of Interest</p>
                <p id="P32">Sem A.O.F Rikken has nothing to declare. Willem L. Bor has nothing to declare. Abi Selvarajah has nothing to declare. Kai L. Zheng has nothing to declare. Amy Hack has nothing to declare. C. Michael Gibson serves as a scientific advisory to CeleCor Therapeutics, Inc. Christopher B. Granger serves as a scientific advisory to CeleCor Therapeutics, Inc. Barry S. Coller is a founder of CeleCor Therapeutics, Inc., which is developing zalunfiban for human use, and is an equity owner in CeleCor and serves as a paid scientific advisor to CeleCor. Ohad Bentur has nothing to declare. Arnoud W.J. van ’t Hof serves as a scientific advisor to CeleCor Therapeutics, Inc. Jurriën M. ten Berg serves as a scientific advisor to CeleCor Therapeutics, Inc.</p>
              </fn>
              <fn id="FN2">
                <p id="P33">Supplementary materials</p>
                <p id="P34"><xref rid="SD1" ref-type="supplementary-material">Supplementary material</xref> associated with this article can be found, in the online version, at doi:<ext-link xlink:href="https://doi.org/10.1016/j.ahj.2023.04.009" ext-link-type="uri">10.1016/j.ahj.2023.04.009</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><name><surname>Jollis</surname><given-names>JG</given-names></name>, <name><surname>Granger</surname><given-names>CB</given-names></name>, <name><surname>Zègre-Hemsey</surname><given-names>JK</given-names></name>, <etal/><article-title>Treatment time and in-hospital mortality among patients with ST-segment elevation myocardial infarction, 2018-2021</article-title>. <source>Jama</source><year>2022</year>;<volume>328</volume>:<fpage>2033</fpage>–<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2022.20149</pub-id>.<pub-id pub-id-type="pmid">36335474</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><name><surname>Lawton</surname><given-names>JS</given-names></name>, <name><surname>Tamis-Holland</surname><given-names>JE</given-names></name>, <name><surname>Bangalore</surname><given-names>S</given-names></name>, <etal/><article-title>2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines</article-title>. <source>J Am Coll Cardiol</source>. <year>2022</year>;<volume>79</volume>:<fpage>e21</fpage>–<lpage>e129</lpage>.doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2021.09.006</pub-id>.<pub-id pub-id-type="pmid">34895950</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><name><surname>Ibanez</surname><given-names>B</given-names></name>, <name><surname>James</surname><given-names>S</given-names></name>, <name><surname>Agewall</surname><given-names>S</given-names></name>, <etal/><article-title>2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation</article-title>. <source>Eur Heart J</source><year>2018</year>;<volume>39</volume>:<fpage>119</fpage>–<lpage>77</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/ehx393</pub-id> .<pub-id pub-id-type="pmid">28886621</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><name><surname>Zeymer</surname><given-names>U</given-names></name>, <name><surname>Ludman</surname><given-names>P</given-names></name>, <name><surname>Danchin</surname><given-names>N</given-names></name>, <etal/><article-title>Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: The ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology</article-title>. <source>Eur Heart J</source><year>2021</year>;<volume>42</volume>:<fpage>4536</fpage>–<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/ehab342</pub-id> .<pub-id pub-id-type="pmid">34389857</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><name><surname>Gödicke</surname><given-names>J</given-names></name>, <name><surname>Flather</surname><given-names>M</given-names></name>, <name><surname>Noc</surname><given-names>M</given-names></name>, <etal/><article-title>Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies</article-title>. <source>Am Heart J</source><year>2005</year>;<volume>150</volume>:<fpage>1015.e11</fpage>–<lpage>1015.e17</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ahj.2005.07.026</pub-id> .</mixed-citation>
              </ref>
              <ref id="R6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><name><surname>De Luca</surname><given-names>G</given-names></name>, <name><surname>Gibson</surname><given-names>CM</given-names></name>, <name><surname>Bellandi</surname><given-names>F</given-names></name>, <etal/><article-title>Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis</article-title>. <source>Heart</source><year>2008</year>;<volume>94</volume>:<fpage>1548</fpage>–<lpage>58</lpage>. doi:<pub-id pub-id-type="doi">10.1136/hrt.2008.141648</pub-id> .<pub-id pub-id-type="pmid">18474534</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><name><surname>Van’t Hof</surname><given-names>AWJ</given-names></name>, <name><surname>Ten Berg</surname><given-names>J</given-names></name>, <name><surname>Heestermans</surname><given-names>T</given-names></name>, <etal/><article-title>Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial</article-title>. <source>Lancet (London, England)</source><year>2008</year>;<volume>372</volume>:<fpage>537</fpage>–<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(08)61235-0</pub-id>.<pub-id pub-id-type="pmid">18707985</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><name><surname>ten Berg</surname><given-names>JM</given-names></name>, <name><surname>van ’t Hof</surname><given-names>AWJ</given-names></name>, <name><surname>Dill</surname><given-names>T</given-names></name>, <etal/><article-title>Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome</article-title>. <source>J Am Coll Cardiol</source><year>2010</year>;<volume>55</volume>:<fpage>2446</fpage>–<lpage>55</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacc.2009.11.091</pub-id>.<pub-id pub-id-type="pmid">20510211</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><name><surname>Mehilli</surname><given-names>J</given-names></name>, <name><surname>Kastrati</surname><given-names>A</given-names></name>, <name><surname>Schulz</surname><given-names>S</given-names></name>, <etal/><article-title>Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial</article-title>. <source>Circulation</source><year>2009</year>;<volume>119</volume>:<fpage>1933</fpage>–<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.818617</pub-id>.<pub-id pub-id-type="pmid">19332467</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><name><surname>Ellis</surname><given-names>SG</given-names></name>, <name><surname>Tendera</surname><given-names>M</given-names></name>, <name><surname>de Belder</surname><given-names>MA</given-names></name>, <etal/><article-title>Facilitated PCI in patients with ST-elevation myocardial infarction</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>358</volume>:<fpage>2205</fpage>–<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa0706816</pub-id> .<pub-id pub-id-type="pmid">18499565</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><name><surname>Gargiulo</surname><given-names>G</given-names></name>, <name><surname>Giacoppo</surname><given-names>D</given-names></name>, <name><surname>Jolly</surname><given-names>SS</given-names></name>, <etal/><article-title>Effects on mortality and major bleeding of radial versus femoral artery access for coronary angiography or percutaneous coronary intervention: meta-analysis of individual patient data from 7 multicenter randomized clinical trials</article-title>. <source>Circulation</source><year>2022</year>;<volume>146</volume>:<fpage>1329</fpage>–<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.122.061527</pub-id>.<pub-id pub-id-type="pmid">36036610</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>Q</given-names></name>, <name><surname>Yin</surname><given-names>J</given-names></name>, <name><surname>Si</surname><given-names>L</given-names></name>. <article-title>Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI</article-title>. <source>Int J Cardiol</source><year>2013</year>;<volume>162</volume>(<issue>3</issue>):<fpage>210</fpage>–<lpage>19</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijcard.2012.06.001</pub-id>.<pub-id pub-id-type="pmid">22769575</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><name><surname>Kereiakes</surname><given-names>DJ</given-names></name>, <name><surname>Henry</surname><given-names>TD</given-names></name>, <name><surname>DeMaria</surname><given-names>AN</given-names></name>, <etal/><article-title>First human use of RUC-4: a nonactivating second-generation small-molecule platelet glycoprotein IIb/IIIa (Integrin <italic toggle="yes">α</italic>IIb<italic toggle="yes">β</italic>3) inhibitor designed for subcutaneous point-of-care treatment of ST-segment–elevation myocardial infarction</article-title>. <source>J Am Heart Assoc</source><year>2020</year>;<volume>9</volume>:<fpage>e016552</fpage>. doi:<pub-id pub-id-type="doi">10.1161/JAHA.120.016552</pub-id>.<pub-id pub-id-type="pmid">32844723</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><name><surname>Bor</surname><given-names>WL</given-names></name>, <name><surname>Zheng</surname><given-names>KL</given-names></name>, <name><surname>Tavenier</surname><given-names>AH</given-names></name>, <etal/><article-title>Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction</article-title>. <source>EuroIntervention</source><year>2021</year>;<volume>17</volume>:<fpage>e401</fpage>–<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.4244/EIJ-D-21-00287</pub-id>.<pub-id pub-id-type="pmid">34031019</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><name><surname>Rikken</surname><given-names>SAOF</given-names></name>, <name><surname>Storey</surname><given-names>RF</given-names></name>, <name><surname>Andreotti</surname><given-names>F</given-names></name>, <etal/><article-title>Parenteral antiplatelet drugs in ST-elevation myocardial infarction: current status and future directions</article-title>. <source>Thromb Haemost</source><year>2023</year>;<volume>123</volume>(<issue>2</issue>):<fpage>150</fpage>–<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-0042-1753479</pub-id> .<pub-id pub-id-type="pmid">36075236</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><name><surname>Bentur</surname><given-names>OS</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Jiang</surname><given-names>CS</given-names></name>, <etal/><article-title>Application of auxiliary verifynow point-of-care assays to assess the pharmacodynamics of RUC-4, a novel <italic toggle="yes">α</italic>llb<italic toggle="yes">β</italic>3 receptor antagonist</article-title>. <source>TH Open</source><year>2021</year>;<volume>05</volume>:<fpage>e449</fpage>–<lpage>60</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-0041-1732343</pub-id> .</mixed-citation>
              </ref>
              <ref id="R17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><name><surname>Chesebro</surname><given-names>JH</given-names></name>, <name><surname>Knatterud</surname><given-names>G</given-names></name>, <name><surname>Roberts</surname><given-names>R</given-names></name>, <etal/><article-title>Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge</article-title>. <source>Circulation</source><year>1987</year>;<volume>76</volume>:<fpage>142</fpage>–<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.1161/01.CIR.76.1.142</pub-id> .<pub-id pub-id-type="pmid">3109764</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><name><surname>Gibson</surname><given-names>CM</given-names></name>, <name><surname>Cannon</surname><given-names>CP</given-names></name>, <name><surname>Murphy</surname><given-names>SA</given-names></name>, <etal/><article-title>Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs</article-title>. <source>Circulation</source><year>2000</year>;<volume>101</volume>:<fpage>125</fpage>–<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.1161/01.CIR.101.2.125</pub-id>.<pub-id pub-id-type="pmid">10637197</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><name><surname>Brodie</surname><given-names>BR</given-names></name>, <name><surname>Stuckey</surname><given-names>TD</given-names></name>, <name><surname>Hansen</surname><given-names>C</given-names></name>, <name><surname>Muncy</surname><given-names>D</given-names></name>. <article-title>Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction</article-title>. <source>Am J Cardiol</source><year>2000</year>;<volume>85</volume>:<fpage>13</fpage>–<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0002-9149(99)00598-6</pub-id>.<pub-id pub-id-type="pmid">11078229</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><name><surname>Stone</surname><given-names>GW</given-names></name>, <name><surname>Cox</surname><given-names>D</given-names></name>, <name><surname>Garcia</surname><given-names>E</given-names></name>, <etal/><article-title>Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials</article-title>. <source>Circulation</source><year>2001</year>;<volume>104</volume>:<fpage>636</fpage>–<lpage>41</lpage>. doi:<pub-id pub-id-type="doi">10.1161/hc3101.093701</pub-id>.<pub-id pub-id-type="pmid">11489767</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><name><surname>Sianos</surname><given-names>G</given-names></name>, <name><surname>Papafaklis</surname><given-names>MI</given-names></name>, <name><surname>Serruys</surname><given-names>PW</given-names></name>. <article-title>Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention</article-title>. <source>J Invasive Cardiol</source><year>2010</year>;<volume>22</volume>(<issue>10 Suppl B</issue>):<fpage>6B</fpage>–<lpage>14B 20947930</lpage>.<pub-id pub-id-type="pmid">20048390</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><name><surname>Mehran</surname><given-names>R</given-names></name>, <name><surname>Rao</surname><given-names>SV</given-names></name>, <name><surname>Bhatt</surname><given-names>DL</given-names></name>, <etal/><article-title>Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium</article-title>. <source>Circulation</source><year>2011</year>;<volume>123</volume>:<fpage>2736</fpage>–<lpage>47</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.009449</pub-id>.<pub-id pub-id-type="pmid">21670242</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><name><surname>Keeley</surname><given-names>EC</given-names></name>, <name><surname>Boura</surname><given-names>JA</given-names></name>, <name><surname>Grines</surname><given-names>CL</given-names></name>. <article-title>Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials</article-title>. <source>Lancet</source><year>2003</year>;<volume>361</volume>:<fpage>13</fpage>–<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(03)12113-7</pub-id>.<pub-id pub-id-type="pmid">12517460</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><name><surname>Armstrong</surname><given-names>PW</given-names></name>, <name><surname>Gershlick</surname><given-names>AH</given-names></name>, <name><surname>Goldstein</surname><given-names>P</given-names></name>, <etal/><article-title>Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction</article-title>. <source>N Engl J Med</source><year>2013</year>;<volume>368</volume>:<fpage>1379</fpage>–<lpage>87</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1301092</pub-id>.<pub-id pub-id-type="pmid">23473396</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><name><surname>Burzotta</surname><given-names>F</given-names></name>, <name><surname>Crea</surname><given-names>F</given-names></name>. <article-title>Thrombus-aspiration: a victory in the war against no reflow</article-title>. <source>Lancet</source><year>2008</year>;<volume>371</volume>:<fpage>1889</fpage>–<lpage>90</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(08)60808-9</pub-id> .<pub-id pub-id-type="pmid">18539205</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><name><surname>Niccoli</surname><given-names>G</given-names></name>, <name><surname>Burzotta</surname><given-names>F</given-names></name>, <name><surname>Galiuto</surname><given-names>L</given-names></name>, <name><surname>Crea</surname><given-names>F</given-names></name>. <article-title>Myocardial No-Reflow in Humans</article-title>. <source>JACC</source><year>2009</year>;<volume>54</volume>:<fpage>281</fpage>–<lpage>92</lpage>. doi:<pub-id pub-id-type="doi">10.1016/jjacc.2009.03.054</pub-id>.<pub-id pub-id-type="pmid">19608025</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><name><surname>Svilaas</surname><given-names>T</given-names></name>, <name><surname>Vlaar</surname><given-names>PJ</given-names></name>, <name><surname>van der Horst</surname><given-names>IC</given-names></name>, <etal/><article-title>Thrombus aspiration during primary percutaneous coronary intervention</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>358</volume>:<fpage>557</fpage>–<lpage>67</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa0706416</pub-id>.<pub-id pub-id-type="pmid">18256391</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><name><surname>Jolly</surname><given-names>SS</given-names></name>, <name><surname>Cairns</surname><given-names>JA</given-names></name>, <name><surname>Yusuf</surname><given-names>S</given-names></name>, <etal/><article-title>Randomized trial of primary PCI with or without routine manual thrombectomy</article-title>. <source>N Engl J Med</source><year>2015</year>;<volume>372</volume>:<fpage>1389</fpage>–<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1415098</pub-id>.<pub-id pub-id-type="pmid">25853743</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><name><surname>Fröbert</surname><given-names>O</given-names></name>, <name><surname>Lagerqvist</surname><given-names>B</given-names></name>, <name><surname>Olivecrona</surname><given-names>GK</given-names></name>, <etal/><article-title>Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction</article-title>. <source>N Engl J Med</source><year>2013</year>;<volume>369</volume>:<fpage>1587</fpage>–<lpage>97</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1308789</pub-id>.<pub-id pub-id-type="pmid">23991656</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><name><surname>Jolly</surname><given-names>SS</given-names></name>, <name><surname>James</surname><given-names>S</given-names></name>, <name><surname>Džavík</surname><given-names>V</given-names></name>, <etal/><article-title>Thrombus aspiration in ST-segment–elevation myocardial infarction</article-title>. <source>Circulation</source><year>2017</year>;<volume>135</volume>:<fpage>143</fpage>–<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.025371</pub-id>.<pub-id pub-id-type="pmid">27941066</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><name><surname>Elgendy</surname><given-names>IY</given-names></name>, <name><surname>Huo</surname><given-names>T</given-names></name>, <name><surname>Bhatt</surname><given-names>DL</given-names></name>, <name><surname>Bavry</surname><given-names>AA</given-names></name>. <article-title>Is Aspiration thrombectomy beneficial in patients undergoing primary percutaneous coronary intervention?</article-title><source>Circ Cardiovasc Interv</source><year>2015</year>;<volume>8</volume>:<fpage>e002258</fpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.114.002258</pub-id>.<pub-id pub-id-type="pmid">26175531</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><name><surname>Montalescot</surname><given-names>G</given-names></name>, <name><surname>van ’t Hof</surname><given-names>AW</given-names></name>, <name><surname>Lapostolle</surname><given-names>F</given-names></name>, <etal/><article-title>Prehospital ticagrelor in ST-segment elevation myocardial infarction</article-title>. <source>N Engl J Med</source><year>2014</year>;<volume>371</volume>:<fpage>1016</fpage>–<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1056/nejmoa1407024</pub-id>.<pub-id pub-id-type="pmid">25175921</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><name><surname>Silvain</surname><given-names>J</given-names></name>, <name><surname>Storey</surname><given-names>RF</given-names></name>, <name><surname>Cayla</surname><given-names>G</given-names></name>, <etal/><article-title>P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study</article-title>. <source>Thromb Haemost</source><year>2016</year>;<volume>116</volume>:<fpage>369</fpage>–<lpage>78</lpage>. doi:<pub-id pub-id-type="doi">10.1160/TH15-12-0944</pub-id>.<pub-id pub-id-type="pmid">27196998</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><name><surname>De Luca</surname><given-names>G</given-names></name>, <name><surname>Bellandi</surname><given-names>F</given-names></name>, <name><surname>Huber</surname><given-names>K</given-names></name>, <etal/><article-title>Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient’s data meta-analysis</article-title>. <source>J Thromb Haemost</source><year>2011</year>;<volume>9</volume>:<fpage>2361</fpage>–<lpage>70</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1538-7836.2011.04513.x</pub-id>.<pub-id pub-id-type="pmid">21929513</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><name><surname>Karathanos</surname><given-names>A</given-names></name>, <name><surname>Lin</surname><given-names>Y</given-names></name>, <name><surname>Dannenberg</surname><given-names>L</given-names></name>, <etal/><article-title>Routine glycoprotein IIb/IIIa inhibitor therapy in ST-segment elevation myocardial infarction: a meta-analysis</article-title>. <source>Can J Cardiol</source><year>2019</year>;<volume>35</volume>:<fpage>1576</fpage>–<lpage>88</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cjca.2019.05.003</pub-id> .<pub-id pub-id-type="pmid">31542257</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><name><surname>Gold</surname><given-names>HK</given-names></name>, <name><surname>Garabedian</surname><given-names>HD</given-names></name>, <name><surname>Dinsmore</surname><given-names>RE</given-names></name>, <etal/><article-title>Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators</article-title>. <source>Circulation</source><year>1997</year>;<volume>95</volume>:<fpage>1755</fpage>–<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1161/01.CIR.95.7.1755</pub-id>.<pub-id pub-id-type="pmid">9107158</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><name><surname>Heestermans</surname><given-names>T</given-names></name>, <name><surname>van ’t Hof</surname><given-names>AWJ</given-names></name>, <name><surname>ten Berg</surname><given-names>JM</given-names></name>, <etal/><article-title>The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the ongoing tirofiban in myocardial evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy</article-title>. <source>Am Heart J</source><year>2010</year>;<volume>160</volume>:<fpage>1079</fpage>–<lpage>84</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ahj.2010.08.039</pub-id>.<pub-id pub-id-type="pmid">21146661</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><name><surname>Silvain</surname><given-names>J</given-names></name>, <name><surname>Collet</surname><given-names>J-P</given-names></name>, <name><surname>Nagaswami</surname><given-names>C</given-names></name>, <etal/><article-title>Composition of coronary thrombus in acute myocardial infarction</article-title>. <source>J Am Coll Cardiol</source><year>2011</year>;<volume>57</volume>:<fpage>1359</fpage>–<lpage>67</lpage>. doi:<pub-id pub-id-type="doi">10.1016/jjacc.2010.09.077</pub-id>.<pub-id pub-id-type="pmid">21414532</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><name><surname>De Luca</surname><given-names>G</given-names></name>, <name><surname>van’t Hof</surname><given-names>AWJ</given-names></name>, <name><surname>Gibson</surname><given-names>CM</given-names></name>, <etal/><article-title>Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation)</article-title>. <source>Am J Cardiol</source><year>2015</year>;<volume>115</volume>:<fpage>711</fpage>–<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amjcard.2014.12.030</pub-id>.<pub-id pub-id-type="pmid">25655867</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><name><surname>Rikken</surname><given-names>SAOF</given-names></name>, <name><surname>Selvarajah</surname><given-names>A</given-names></name>, <name><surname>Hermanides</surname><given-names>RS</given-names></name>, <etal/><article-title>Pre-hospital treatment with zalunfiban (RUC-4) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the CELEBRATE trial</article-title>. <source>Am Heart J</source><year>2023</year>;<volume>258</volume>:<fpage>119</fpage>–<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.1016/J.AHJ.2022.12.015</pub-id>.<pub-id pub-id-type="pmid">36592878</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig position="float" id="F1">
              <label>Figure 1</label>
              <caption>
                <p id="P35">Study profile. PK/PD = pharmacokinetic/pharmacodynamic. The angiographic population was composed of all patients with evaluable angiographic data and without a definite type 2 myocardial infarction. A second angiographic population without miss</p>
              </caption>
              <graphic xlink:href="nihms-1940242-f0001" position="float"/>
            </fig>
            <fig position="float" id="F2">
              <label>Figure 2</label>
              <caption>
                <p id="P36">Dose-dependent effects for zalunfiban on three angiographic indices. TIMI; Thrombolysis in myocardial infarction. Dose-dependent effects per angiographic outcome of interest were assessed with the Cochran-Armitage test.</p>
              </caption>
              <graphic xlink:href="nihms-1940242-f0002" position="float"/>
            </fig>
            <table-wrap position="float" id="T1" orientation="landscape">
              <label>Table I.</label>
              <caption>
                <p id="P37">Demographics, baseline characteristics, prehospital treatment and time limits</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="middle" rowspan="1" colspan="1">Characteristic</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">0.075 mg/kg (<italic toggle="yes">N</italic>=7)</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">0.090 mg/kg (<italic toggle="yes">N</italic>=9)</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">0.110 mg/kg (<italic toggle="yes">N</italic>=8)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Age, years, mean (SD)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">60 (13)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">63 (14)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">66 (13)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Female sex, <italic toggle="yes">n</italic> (%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2/7 (28.6%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2/9 (22.2%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">3/8 (37.6%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Caucasian race, <italic toggle="yes">n</italic> (%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">6/7 (85.8%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">9/9 (100%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">8/8 (100%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Body Mass Index (kg/m2), mean (SD)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">26.8 (2.5)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">26.0 (3.6)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">24.6 (2.8)</td>
                  </tr>
                  <tr>
                    <td colspan="4" align="left" valign="middle" rowspan="1">
                      <bold>Cardiovascular risk factors, <italic toggle="yes">n</italic> (%)</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Hypercholesterolemia</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2/7 (28.6%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2/9 (22.2%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">3/8 (37.5%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Hypertension</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1/7 (14.3%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">3/9 (33.3%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">5/8 (62.5%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Diabetes mellitus</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/8 (0%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Peripheral arterial disease</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/8 (0%)</td>
                  </tr>
                  <tr>
                    <td colspan="4" align="left" valign="middle" rowspan="1">
                      <bold>Medical history, <italic toggle="yes">n</italic> (%)</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Prior myocardial infarction</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2/9 (22.2%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1/8 (12.5%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Prior PCI</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2/9 (22.2%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1/8 (12.5%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Prior CABG</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/8 (0%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">History of stroke</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/8 (0%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">History of anemia</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/8 (0%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">History of thrombocytopenia</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/8 (0%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Chronic kidney disease</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/8 (0%)</td>
                  </tr>
                  <tr>
                    <td colspan="4" align="left" valign="middle" rowspan="1">
                      <bold>Pretreatment, <italic toggle="yes">n</italic> (%)</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Aspirin 500 mg i.v.</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">7/7 (100%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">9/9 (100%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">8/8 (100%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Ticagrelor 180 mg p.o</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">7/7 (100%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">9/9 (100%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">8/8 (100%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Unfractionated heparin 5000 IU i.v.</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">7/7 (100%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">9/9 (100%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">8/8 (100%)</td>
                  </tr>
                  <tr>
                    <td colspan="4" align="left" valign="middle" rowspan="1">
                      <bold>Median timing milestones</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Time from symptom onset to FMC, minutes</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">27</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">60</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">57</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Time from symptom onset to ECG diagnosis, minutes</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">36</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">73</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">67</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Time from symptom onset to pretreatment, minutes</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">41</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">74</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">70</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Time from symptom onset to arrival emergency room, minutes</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">74</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">110</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">102</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Time from symptom onset to zalunfiban administration, minutes</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">90</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">122</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">129</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Time from symptom onset to angiogram, minutes<xref rid="TFN1" ref-type="table-fn">*</xref></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">~ 100-105</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">~ 132-137</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">~ 139-144</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN1">
                  <label>*</label>
                  <p id="P38">10-15 minutes were added to time from symptom onset to zalunfiban administration, as these were estimates.</p>
                </fn>
                <fn id="TFN2">
                  <p id="P39">CABG, coronary artery bypass graft; ECG, electrocardio-gram; FMC, first medical contact; IU, international units; IV, intravenous; PCI, percutaneous coronary intervention; SD, standard deviation.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap position="float" id="T2" orientation="landscape">
              <label>Table II.</label>
              <caption>
                <p id="P40">Safety outcomes</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="middle" rowspan="1" colspan="1">Bleeding according to BARC classification</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">0.075 mg/kg (<italic toggle="yes">N</italic>=7)</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">0.090 mg/kg (<italic toggle="yes">N</italic>=9)</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">0.110 mg/kg (<italic toggle="yes">N</italic>=8)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">BARC 1</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">3/7 (42.9%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">4/9 (44.4%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2/8 (25.0%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">BARC 2</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1/7 (14.3%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1/8 (12.5%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">BARC 3a</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1/8 (12.5%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">BARC 3b</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1/7 (14.3%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/0 (0%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">BARC 3c</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/0 (0%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">BARC 4</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/0 (0%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">BARC 5</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/0 (0%)</td>
                  </tr>
                  <tr>
                    <td colspan="4" align="left" valign="middle" rowspan="1">
                      <bold>Bleeding according to anatomic site and severity</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Injection site bruising</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2/7 (28.6%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">4/9 (44.4%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1/8 (12.5%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Mild vascular access site bleeding</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2/7 (28.6%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">2/8 (25.0%)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Severe vascular access site bleeding</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1/7 (14.3%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0/9 (0%)</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">1/8 (12.5%)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN3">
                  <p id="P41">Patients with more than one bleeding event are counted only once using the highest grade.</p>
                </fn>
                <fn id="TFN4">
                  <p id="P42">BARC, bleeding academic research consortium.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
